投稿時間:2023-12-09 06:10:37 RSSフィード2023-12-09 06:00分まとめ(10件)

カテゴリー	サイト名	記事タイトル	リンクURL	頻出ワード・要約等	登録日
AWS	AWS Partner Network (APN) Blog	Building a Streaming Pipeline with Minimal Effort Using Amazon Kinesis and Talend	https://aws.amazon.com/blogs/apn/building-a-streaming-pipeline-with-minimal-effort-using-amazon-kinesis-and-talend/	To collect massive amounts of time critical data setting up data streaming pipelines is essential The combination of Talend and Amazon Kinesis provides a complete solution for easily building running and maintaining streaming data pipelines with low operational overhead Learn how Talend with Amazon Kinesis supporting Spark streaming enables an accessible no code methodology for building Spark streaming pipelines leveraging the power of AWS	2023-12-08 20:24:23
海外TECH	AppleInsider - Frontpage News	Apple's vice president of product design leaving in February	https://appleinsider.com/articles/23/12/08/apples-vice-president-of-product-design-leaving-in-february?utm_medium=rss	Tang Tan Apple s vice president of product design is leaving the company in February marking another high level departure in recent history Apple s vice president of product design leaving in February Sources in the company say that the departure is a blow to the company Tang was responsible for making critical decisions about many of Apple s products and had substantial influence over the design of iPhone Apple Watch and AirPods products Read more	2023-12-08 20:38:51
海外TECH	Engadget	CRISPR-based gene editing therapy approved by the FDA for the first time	https://www.engadget.com/crispr-based-gene-editing-therapy-approved-by-the-fda-for-the-first-time-200726474.html?src=rss	In a landmark decision the FDA greenlit two new drugs for the treatment of sickle cell disease in patients and older one of which ーVertex s drug Casgevy ーis the first approved use of genome editing technology CRISPR in the US Bluebird Bio s Lyfgenia also is a cell based gene therapy however it uses a different gene modification technique to deliver tweaked stem cells to the patient Both approvals cultivate new pathways for the treatment of sickle cell disease which is an inherited blood disorder that is characterized by red blood cells that can t properly carry oxygen which leads to painful vaso occlusive crises VOCs and organ damage The disease is particularly common among African Americans and to a lesser extent among Hispanic Americans Bone marrow transplants are currently the only cure for sickle cell disease but they require well matched donors and often involve complications Breaking The U S FDA approves our treatment for SickleCellDisease We are excited to make this treatment available to patients Learn more pic twitter com cyeqvvvnーVertex Pharmaceuticals VertexPharma December While both drug approvals use gene editing techniques Casgevy s CRISPR Cas genome editing works by cutting out or splicing in DNA in select areas Patients first have blood drawn so that their own stem cells can be isolated and edited with CRISPR They then undergo a form of chemotherapy to remove some bone marrow cells so the edited stem cells can be transplanted back in a single infusion Both drug approvals are based on studies that evaluated the effectiveness and safety of the novel therapies in clinical patients With Casgevy study participants reported that they did not experience severe VOCs for at least consecutive months during the month follow up Similarly patients on Lyfgenia did not experience a pain crisis for six to months after the therapy The FDA s decision comes shortly after UK regulators as well as the National Health Regulatory Authority in Bahrain both approved Vertex s Casgevy The approval for a CRISPR based treatment creates opportunity for further innovation in the gene editing space ーfor treatments ranging from cancers to heart diseases to Alzheimer s Gene therapy holds the promise of delivering more targeted and effective treatments especially for individuals with rare diseases where the current treatment options are limited Nicole Verdun director of the Office of Therapeutic Products at the FDA s Center for Biologics Evaluation and Research said Casgevy is still currently under review by the European Medicines Agency This article originally appeared on Engadget at	2023-12-08 20:07:26
海外TECH	Cisco Blog	Cisco Partners and Purpose are Greater Together	https://feedpress.me/link/23532/16488290/cisco-partners-and-purpose-are-greater-together	Last year Cisco introduced Partnering for Purpose where innovation and business goals with environmental social and governance ESG initiatives were highlighted to benefit partners and their customers Cisco added a Partnering for Purpose Category in the sixth Annual Partner Innovation Challenge and of all partner entries for the Innovation Challenge were submitted in this Partnering for Purpose Category It is inspiring to see this response from our global partner community	2023-12-08 20:58:58
科学	NYT > Science	New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most	https://www.nytimes.com/2023/12/08/health/casgevy-lyfgenia-sickle-cell-africa.html	There is no clear path for African patients to get access to the treatments which have multimillion dollar price tags and are highly complex to manufacture and deliver	2023-12-08 20:51:31
詳細記事	ダイヤモンド・オンライン - 新着記事	理系エリート塾の勢力マップ「九州各大手の脅威は英進館」【北海道・東北／中国・四国／九州編】 - 新・理系エリート	https://diamond.jp/articles/-/333344	エリート,大学受験	2023-12-09 05:25:00
詳細記事	ダイヤモンド・オンライン - 新着記事	【無料公開】ゼネコン下請け倒産予備軍2万6000社、コロナ前から倍増！資材高でも価格転嫁できず悲鳴 - Diamond Premiumセレクション	https://diamond.jp/articles/-/334912	diamond,premium,セレクション	2023-12-09 05:20:00
詳細記事	ダイヤモンド・オンライン - 新着記事	「“優秀”な奴は新しいものを生み出せない」エピックソニー創始者が語る、新規事業開発の極意 - ソニー・ホンダの逆襲	https://diamond.jp/articles/-/332901	エピックソニー,エレクトロニクス,ミュージックエンタテインメント	2023-12-09 05:15:00
詳細記事	ダイヤモンド・オンライン - 新着記事	買い得・売り得マンションランキング【名古屋編・全177物件】買い得8位はアリーナシティ、1位は？ - 2023年決定版 インフレ時代の「負けない」マンション売買・管理	https://diamond.jp/articles/-/333303	アリーナ,インフレ,マンション	2023-12-09 05:10:00
詳細記事	ダイヤモンド・オンライン - 新着記事	3メガバンクの「出世・年収」・渋谷の「北朝鮮マンション」が解放されるまで・デロイトパートナーの年収は最大3億円 - ダイヤモンド編集部厳選 必読！今週のニュース3本	https://diamond.jp/articles/-/335254	メガバンク,みずほ銀行,ダイヤモンド	2023-12-09 05:05:00